SecBot SecBot
DEFM14A ·Filed Apr 1, 2026

PEN

Penumbra Inc
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001140361-26-012785
Notable filing: DEFM14A
Actionable Insight ▲ Bullish

Traders should monitor the FTC review process and shareholder voting results. The significant premium suggests limited downside risk, but regulatory uncertainty could create volatility. Boston Scientific shareholders may see temporary dilution from the stock component.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$330.36
T+0 close · Apr 1, 2026 · via day close
Latest settled
−4.42%
T+60 · $315.75
Vs SPY
−18.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $330.36entry
  2. T+1 · 8mo ago −0.15%α −0.62% · $329.87
  3. T+5 · 7mo ago −0.18%α −3.80% · $329.77
  4. T+20 · 7mo ago −1.17%α −11.05% · $326.48
  5. T+60 · 5mo ago −4.42%α −18.58% · $315.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Penumbra Inc is being acquired by Boston Scientific in a mixed cash-and-stock deal valued at $374.00 per share, representing a 26% premium to Penumbra's unaffected stock price. The Penumbra board unanimously recommends approval, citing strategic benefits from Boston Scientific's global scale. Regulatory approvals are pending, including a Second Request from the FTC, with closing expected in 2026.

Key Financial Metrics

Deal Value
$14.7B
Premium
26%
Deal Type
acquisition

Key Facts

  • Deal valued at $374.00 per Penumbra share, combining cash ($374.00) and stock (3.8721 Boston Scientific shares) options for shareholders
  • 26.74% of shares will receive stock consideration, 73.26% will receive cash, subject to proration
  • Perella Weinberg Partners issued a fairness opinion supporting the deal's financial terms
  • Boston Scientific will pay a $900 million termination fee if antitrust approvals are denied
  • FTC issued a Second Request on March 16, 2026, extending the HSR waiting period
  • Special meeting scheduled for May 6, 2026 for shareholder vote

Financial Impact

Approximately $14.7 billion total deal value based on 39.3 million shares outstanding and $374.00 per share price

share priceownership structurerevenuedilution

Risk Factors

  • Regulatory approval risk, particularly from FTC antitrust review
  • Failure to obtain Penumbra shareholder approval
  • Potential delays in closing beyond 2026
  • Integration risks post-closing

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001140361-26-012785
Document: ny20065749x1_defm14a.htm0001140361-26-012785

Track record

11 reports on PEN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
  3. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  4. Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
  5. Jul 30, 202615w ago Press Release Bearish 6/10 Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
  6. May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
  7. May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
  8. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
  9. Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
  10. Apr 1, 202632w ago DEFM14A Bullish 8/10 Viewing Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026